The significance of chimerism monitor in lineage-specific immune cell populations after allogeneic hematopoietic stem cell transplantation

doi:10.3877/cma.j.issn.1674-3903.2017.04.012

Abstract

Abstract:

Allogeneic hematopoietic stem cell transplantation has been accepted as one of the most effective therapy to treat hematological malignancies at home and abroad. The biological characteristics of immune cell subsets are different from each other, and donor cell chimerism after allogeneic hematopoietic stem cell transplantation can be complicated. Therefore, analyzing of donor-type chimerism in lineage-specific immune cell populations plays a significant role in estimating engraftment, predicting disease prognosis and improving survival rate because of its high sensibility and specificity. We reviewed the clinical significance of supervising chimerism in lineage-specific immune cell populations after allogeneic hematopoietic stem cell transplantation.

Key words: Allogeneic hematopoietic stem cell transplantation, Chimerism, Lineage-specific immune cell population

Ruimin Hong, Lixia Sheng, He Huang, Guifang Ouyang. The significance of chimerism monitor in lineage-specific immune cell populations after allogeneic hematopoietic stem cell transplantation[J]. Chinese Journal of Transplantation(Electronic Edition), 2017, 11(04): 245-250.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhyzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3903.2017.04.012

https://zhyzzz.cma-cmc.com.cn/EN/Y2017/V11/I04/245

References 38

1	Jacque N,Nguyen S,Golmard JL, et al. Chimerism analysis in peripheral blood using indel quantitative real-time PCR is a useful tool to predict post-transplant relapse in acute leukemia[J]. Bone Marrow Transplant, 2015, 50(1): 259-265.
2	Czekalska S,Sacha T,Piatkowska-Jakubas B, et al. Evaluation of hematopoietic chimerism after allogeneic bone marrow transplantation by modern molecular techniques (STR-PCR and RQ-PCR)-single center[J]. Przeql Lek, 2010, 67(12): 1282-1291.
3	王椿,万理萍. 同种异基因造血干细胞移植后血细胞嵌合状态动态检测的临床意义[J]. 诊断学理论与实践, 2010, 9(1): 1-5.
4	Lion T. Detection of impending graft rejection and relapse by lingeage-specific chimerism analysis[J]. Methods Mol Med, 2007, 134: 197-216.
5	Marsh RA,Rao MB,Gefen A, et al. Experience with alemtuzumab, fludarabin, and melphalan reduced-intensity conditioning hematopoietic cell transplantation in patients with nonmalignant diseases reveals good outcomes and that the risk of mixed chimerism depends on underlying disease, stem cell source, and alemtuzumab regimen[J]. Biol Blood Marrow Transplant, 2015, 21(8): 1460-1470.
6	Elkaim E,Picard C,Galambrun C, et al. Peripheral blood cells chimerism after unrelated cord blood transplantation in children: kinetics, predictive factors and impact on post-transplant outcome[J]. Br J Haematol, 2014, 16(6): 557-565.
7	Baron F,Sandmaier BM. Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning[J]. Leukemia, 2006, 20(1): 1690-1700.
8	Yang YN,Wang XR,Qin YW, et al. Is there a role for B lymphocyte chimerism in the monitoring of B-acute lymphoblastic leukemia patients receiving allogeneic stem cell transplantation？[J]. Chronic Dis Transl Med, 2015, 1(1): 48-54.
9	Thompson PA,Stingo F,Keating MJ, et al. Long-term follow-up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T-cell chimerism is associated with high relapse risk and inferior survival[J]. Br J Heamatol, 2017, 177(4): 567-77.
10	Broqlie L,Helenowski I,Jennings LJ, et al. Early mixed T-cell chimerism is predictive of pediatric AML or MDS relapse after hematopoietic stem cell transplant[J]. Pediatr Blood Cancer, 2017, 64(9): 1-4.
11	Baron F,Baker JE,Storb R. Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning[J]. Blood, 2004, 104(8): 2254-2262.
12	蒋瑛. 异基因造血干细胞移植后细胞嵌合状态动态监测的临床意义[J]. 中华血液学杂志, 2008, 29(10): 667-671.
13	Childs R,Clave E,Contentin N, et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses[J]. Blood, 1999, 94(9): 3234-3241
14	Keil F,Prinz E,Moser K, et al. Rapid establishment of long-term culture-initiating cells of donor origin after nonmyeloablative allogeneic hematopoietic stem-cell transplantation, and significant prognostic impact of donor T-cell chimerism on stable engraftment and progression-free survival[J]. Transplantation, 2003, 76(1): 230-236.
15	Breuer S,Preuner S,Fritsch G, et al. Early recipient chimerism testing in the T-and NK-cell lineages for risk assessment of graft rejection in pediatric patients undergoing allogeneic stem cell transplantation[J]. Leukemia, 2012, 26(3): 509-519.
16	Matthes-Martin S,Lion T,Haas OA, et al. Lineage-specific chimerism after stem cell transplantation in children following reduced intensity conditioning: potential predictive value of NK cell chimerism for late graft rejection[J]. Leukemia, 2003, 17(1): 1934-1942.
17	Jaksch M,Uzunel M,Remberger M, et al. Molecular monitoring of T-cell chimerism eraly after allogeneic stem cell transplantation may predict the occurrence of acute GVHD grades Ⅱ-Ⅳ[J]. Clin Transplant, 2005, 19(3): 346-349.
18	Minculescu L,Madsen HO,Sengelov H, et al. T-Cell Chimerism is valuable in predicting early mortality in steroid-resistant acute graft-versus-host disease after myeloablative allogeneic cell transplantation[J]. Acta Haematol, 2014, 132(1): 187-192.
19	Jiang Y,Wan L,Qin Y, et al. Chimerism status is correlated to acute graft-versus-host disease after allogeneic stem cell transplantation[J]. Int J Hematol, 2014, 99(3): 323-328.
20	Guz K,Nasilowska B,Tomaszewska A, et al. Real-Time PCR analysis of chimerism in T cell subsets as an early predictor of graft-versus-host disease following allogeneic stem cell transplantation[J]. Ann Transplant, 2015, 20(10): 720-728.
21	陈晓燕. CD3^＋T细胞嵌合率对监测重型再障异基因造血干细胞移植疗效的作用[J]. 热带医学杂志, 2015, 15(12): 1640-1643.
22	Pastore D,Delia M,Mestice A, et al. CD3^＋/Tregs ratio in donor grafts is linked to acute graft-versus-host disease and immunologic recovery after allogeneic peripheral blood stem cell transplantation[J]. Biol Blood Marrow Transplant, 2012, 18(6): 887-893.
23	Juric MK,Shevtson M,Mozes P, et al. B-cell-based and soluble biomarkers in body liquids for predicting acute/chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation[J]. Front Immunol, 2017, 1(16): 1-13.
24	Perruche S,Kleinclauss F,Tmerghien P, et al. B cell allogeneic responses after hematopoietic cell transplantation: Is it time to address this issue？[J]. Transplantation, 2005, 79(Suppl 3): S37-S39.
25	Ran R,Elizabeth OH,Alison WL, et al. Early donor chimerism levels predict relapse and survival after allogeneic stem-cell transplantation with reduced intensity conditioning[J]. Biol Blood Marrow Transplant, 2014, 20(11): 1758-1766.
26	Lee HC,Saliba RM,Rondon G, et al. Mixed T-lymphocyte chimerism after allogeneic hematopoietic transplantation is predictive for relapse of AML/MDS[J]. Biol Blood Marrow Transplant, 2015, 21(11): 1948-1954.
27	Yang YN,Wang XR,Qin YW, et al. Is there a role for B lymphocyte chimerism in the monitoring of B-acute lymphoblastic leukemia patients receiving allogeneic stem cell transplantation？[J]. Chronic Dis Transl Med, 2015, 1(1): 48-54.
28	Jiang Y,Wan L,Qin Y, et al. Donor chimerism of B cells and nature killer cells provides useful information to predict hematologic relapse following allogeneic hematopoietic stem cell transplantation[J]. PLoS One, 2015, 10(7): e0133671.
29	Mo XD,Lv M,Huang XJ. Preventing relapse after haematopoietic stem celltransplantation for acute leukaemia: the role of post-transplantation minimal residual disease (MRD) monitoring and MRD-directed intervention[J]. Br J Haematol. [Epub ahead of print]
30	中华医学会血液学分会干细胞应用学组. 中国异基因造血干细胞移植治疗血液系统疾病专家共识(Ⅱ)——移植后白血病复发(2016年版)[J]. 中华血液学杂志, 2016, 37(10): 846-851.
31	Horn B,Wahlstrom JT,Melton A, et al. Early mixed chimerism-based preemptive immunotherapy in children undergoing allogeneic hematopoietic stem cell transplantation for acute leukemia[J]. Pediatr Blood Cancer, 2017, 64(8): 1-5
32	Inagaki J,Fukano R,Nishikawa T, et al. Outcomes of immunological interventions for mixed chimerism following allogeneic stem cell transplantation in children with juvenile myelomonocytic leukemia[J]. Pediatr Blood Cancer, 2013, 60(1): 116-120.
33	Krishnamurthy P,Potter VT,Barber LD. Outcome of donor lymphocyte infusion after T cell-depleted allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia andmyelodysplastic syndromes[J]. Biol Blood Marrow Transplant, 2013, 19(1): 562-568.
34	Sairafi D,Remberger M,Uhlin M, et al. Leukemia lineage-specific chimerism analysis and molecular monitoring improve outcome of donor lymphocyte infusions[J]. Biol Blood Marrow Transplant, 2010, 16(12): 1728-1737.
35	Antin JH,Childs R,Ipovich AH, et al. Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietie transplantation：recommendation from a workshop at the 2001 Tandem Meeting of the Intemational Bone Marrow Transplant Registry and the American Society of Blood and Marrow TranspIantation[J]. Biol Blood Marrow Transplant, 2001, 7(1): 473-485.
36	Massenkeil G,Nagy M,Lawang M, et al. Reduced intensity conditioning and prophylactic DLI can cure patients with high-risk acute leukaemias if complete donor chimerism can be achieved[J]. Bone Marrow Transplant, 2003, 31(5): 339-345.
37	Umeda K,Adachi S,Tanaka S, et al. Comparison of second transplantation and donor lymphocyte infusion for donor mixed chimerism after allogeneic stem cell transplantation for nonmalignant diseases[J]. Pediatr Blood Cancer, 2016, 63(12): 2221-2229.
38	张永清,施兵,刘丽辉, 等. 亲缘单倍体供者与非血缘相合供者造血干细胞移植的临床疗效研究[J/CD]. 中华细胞与干细胞杂志：电子版, 2015, 5(2): 14-18.

[1]	Xin Kong, Baoquan Song, Yin Liu, Jian Zhang, Huiying Qiu, Depei Wu. Intractable hiccup induced by allogeneic hematopoietic stem cell transplantation: a case report [J]. Chinese Journal of Transplantation(Electronic Edition), 2023, 17(04): 253-255.
[2]	min Chen, Tianzhong Pan, Zimin Sun. Iron removal therapy for poor implantation after allogeneic hematopoietic stem cell transplantation: a case report [J]. Chinese Journal of Transplantation(Electronic Edition), 2022, 16(03): 168-171.
[3]	Jing Zhao, Shuyi Ding, Xiaoyu Zhou, Jianli Zhang, Liwei Xu, Lichen Zhang, Jiali Yan, Qiong Cheng, Nian Liu, Aiyun Jin. The variation and impact factors of quality of life in chronic graft versus host disease patients after allogeneic hematopoietic stem cell transplantation [J]. Chinese Journal of Transplantation(Electronic Edition), 2022, 16(03): 153-159.
[4]	Heng Liu, Tao Wu. Research progress of ibrutinib in the treatment of chronic graft-versus-host disease [J]. Chinese Journal of Transplantation(Electronic Edition), 2021, 15(05): 317-320.
[5]	Yan Liu, Tao Wu, Dongfeng Mao, Lingling Yu, Hai Bai. A case report of human leukocyte antigen matched allogenetic hematopoietic stem cell transplantation in the treatment of refractory polygenic mutation in acute myeloid leukemia [J]. Chinese Journal of Transplantation(Electronic Edition), 2021, 15(04): 229-231.
[6]	Chaolang Zhang, Xiaoping Guo, Fenying Zhao, Xiaojun Xu. Infantile diarrhea accompanied with regenerating islet-derived protein 3 alpha elevation after allogeneic hematopoietic stem cell transplantation: two cases report [J]. Chinese Journal of Transplantation(Electronic Edition), 2021, 15(02): 116-118.
[7]	Yong Zhang, Hebing Zhou. B cell lymphoma/leukemia-2 inhibitor plus azacytidine regimen for two cases of relapse acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation [J]. Chinese Journal of Transplantation(Electronic Edition), 2021, 15(01): 45-48.
[8]	Qunfang Ge, Honglin Zhou, Guifang Ouyang. Allogenic hematopoietic stem cell transplantation for acute leukemia concurrent with cardiac hypertrophy: two cases report and literature review [J]. Chinese Journal of Transplantation(Electronic Edition), 2019, 13(04): 310-313.
[9]	Huguang Zeng, Ju Sun, Wenbin Liu, Dijiong Wu, Huijin Hu, Qinghong Yu, Yiping Shen, Yuhong Zhou, Baodong Ye. A case of membrane nephropathy after allogeneic hematopoietic stem cell transplantation treatment with human amniotic epithelial cells [J]. Chinese Journal of Transplantation(Electronic Edition), 2019, 13(03): 242-244.
[10]	Fang Yang, Lixia Sheng, Guifang Ouyang. Sequential therapy of allogeneic hematopoietic stem cell transplantation after autologous hematopoietic stem cell transplantation for plasmablastic lymphoma: a case report [J]. Chinese Journal of Transplantation(Electronic Edition), 2018, 12(03): 128-130.
[11]	Fang Yang, Lixia Sheng, Guifang Ouyang. Research progress of donor NK cells and chimerism in allogeneic hematopoietic stem cell transplantation [J]. Chinese Journal of Transplantation(Electronic Edition), 2018, 12(02): 91-96.
[12]	Wenhui Liu, Tao Wu, Xi Zhang. Advances in mesenchymal stem cells combined with thrombopoietin receptor agonists in platelet recovery after allogeneic hematopoietic stem cell transplantation [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2023, 13(04): 242-246.
[13]	Yaqun Hong, Xiaofan Li. Advances of interlukin-10 in graft versus host disease [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2020, 10(05): 286-291.
[14]	Manpin Zhang, Xia Qin, Chengjuan Luo, Jianmin Wang, Changying Luo, Jing Chen. Risk factors and prognosis of Epstein-Barr virus DNAemia in children with aplastic anemia after allogeneic hematopoietic stem cell transplantation [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2020, 10(02): 90-96.
[15]	Jie Zhao, Lan Wang, Hongmei Yang, Yi He, Hong Yuan. Autoimmune hemolytic anemia following allogeneic hematopoietic stem cell transplantation in a patient: serological detection methods for mimicking antibodies and blood transfusion strategy [J]. Chinese Journal of Clinicians(Electronic Edition), 2022, 16(05): 452-456.

Please choose a citation manager

Content to export